NCT07019090View on ClinicalTrials.gov

Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

January 19, 2027

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

HSK44459

HSK44459

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY